Thu.Aug 08, 2024

article thumbnail

Bavarian Nordic scores $157M contract to replenish US supplies of smallpox/mpox vaccine Jynneos

Fierce Pharma

Following the commercial launch of Bavarian Nordic’s smallpox/mpox vaccine Jynneos earlier this year, the Danish company has locked up yet another supply agreement with the U.S. government. | The Biomedical Advanced Research and Development Authority (BARDA) is handing Bavarian Nordic $156.8 million to “partly replenish” Jynneos vaccine stocks in response to the 2022 outbreak of mpox, the disease formerly known as monkeypox.

article thumbnail

Wearable Tech is Empowering Patients To Be Proactive in Their Health

MedCity News

This potential for self-management can reduce the burden on the healthcare system, resulting in fewer doctor visits, lower hospitalization risks, and fewer diagnostic tests as patients can take corrective action earlier or identify issues sooner. The post Wearable Tech is Empowering Patients To Be Proactive in Their Health appeared first on MedCity News.

Patients 129
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Eli Lilly lifts sales guidance by $3B as supplies of Mounjaro and Zepbound recover

Fierce Pharma

While a glut of drugmakers have raised their 2024 financial guidance after the second quarter, those upgraded sales expectations pale in comparison to Eli Lilly’s new forecast for the year. | Lilly, which reported a 36% sales increase year-over-year to $11.3 billion in the second quarter, is raising its guidance for the full year by a staggering $3 billion.

Sales 301
article thumbnail

Why More Than 30% of Rural Hospitals Are at Risk of Closure

MedCity News

More than 700 hospitals across the rural U.S. are at risk of closing due to their financial woes — and for more than half of these hospitals, the risk of closure is immediate, according to a new report. The report argued this is due largely to inadequate reimbursement from health plans. The post Why More Than 30% of Rural Hospitals Are at Risk of Closure appeared first on MedCity News.

article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

Sandoz lifts guidance after Humira biosimilar drives another quarter of sales growth

Fierce Pharma

After taking a market share lead in the crowded Humira biosimilar space and with other key launches in the works, Novartis spinout Sandoz is raising its full-year sales guidance. | The company touts leading biosimilar market share for its version of AbbVie's Humira.

Sales 281
article thumbnail

A Breadcrumb of Serialized Data

Pharmaceutical Commerce

In this part of his Pharma Commerce video interview, Michael Rowe, Two Labs’ Senior Director of DSCSA/Serialization Compliance Services, discusses the state of affairs surrounding the Drug Supply Chain Security Act, along with opportunities for improvement.

Pharma 105

More Trending

article thumbnail

Blue Cross Blue Shield of Tennessee Taps FarmboxRx for Food as Medicine Initiative

MedCity News

Through a new partnership with FarmboxRx, Blue Cross Blue Shield of Tennessee members will receive healthy food deliveries after they complete preventive health screenings, like a diabetic eye exam. The post Blue Cross Blue Shield of Tennessee Taps FarmboxRx for Food as Medicine Initiative appeared first on MedCity News.

Food 98
article thumbnail

Apellis, Sobi's 'enormous' Empaveli win could pressure Novartis in rare kidney diseases: analyst

Fierce Pharma

While Apellis Pharmaceuticals has spent much of the year working around setbacks that derailed the ongoing launch of its geographic atrophy (GA) drug Syfovre, a major phase 3 triumph could open up | Empaveli showed strong efficacy in two rare kidney diseases. The result “exceeded our already high expectations," an Apellis exec said, and it led analysts at Evercore ISI to assign the drug a majority future market share against Novartis’ rival.

article thumbnail

AI biotechs Exscientia and Recursion agree $688m merger

pharmaphorum

Recursion Pharma has agreed to merge with rival AI-powered drug discovery firm Exscientia in an all-stock deal valued at $688 million

Pharma 112
article thumbnail

Citius notches first FDA approval, scoring with Lymphir for cutaneous T-cell lymphoma

Fierce Pharma

A year after it was hit with a rejection from the FDA, Citius Pharmaceuticals has scored an approval for Lymphir to treat cutaneous T-Cell Lymphoma.

FDA 284
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Purdue receives clearance for opioid overdose injector for younger individuals

Pharmaceutical Technology

Coming in response to a rise in teenage overdoses across the US, the Purdue auto-injector device is designed to be used by anyone.

105
105
article thumbnail

Fierce Pharma Asia—The TROP2 ADC race; Another Merck-Daiichi cancer deal; Eisai's molecular glue pact

Fierce Pharma

Three large pharma companies are locked in a high-stakes antibody-drug conjugate race. Merck and Daiichi Sankyo teamed up on a DLL3 T-cell engager. | Three large pharma companies are locked in a high-stakes antibody-drug conjugate race. Merck and Daiichi Sankyo teamed up on a DLL3 T-cell engager. Eisai inked a molecular glue degrader deal with BeyondSpring that could be worth up to $1.5 billion.

Pharma 130
article thumbnail

Pharma Pulse 8/8/24: Addressing Maternal Health Disparities and Driving Change, Abacavir Increases Cardiovascular Risk in Patients With HIV & more

Pharmaceutical Commerce

Business strategies and top news in the biotech / biopharma industry, including market access, supply chain distribution and more.

article thumbnail

Does Roche have buyer's remorse for Flatiron takeover?

pharmaphorum

Roche is said to be considering a sale of cancer data specialist Flatiron Health, just a few years after it bought the company for $1.

Sales 105
article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

US FDA approves Novartis’ Fabhalta in IgAN treatment

Pharmaceutical Technology

Novartis has secured US Food and Drug Administration (FDA) accelerated approval for Fabhalta (iptacopan) to treat igAN.

article thumbnail

Novartis gets FDA OK for first in its trio of IgAN therapies

pharmaphorum

Novartis gets FDA accelerated approval for Fabhalta in IgA nephropathy as it charts a course to blockbuster sales for the drug

FDA 105
article thumbnail

Study reveals AI insights can predict development of disease a decade in advance

PharmaTimes

The study predicted the development of conditions including Alzheimer’s and heart disease

118
118
article thumbnail

Rural America’s Maternity Crisis: How Locum Tenens Can Help Fill Gaps in Rural Hospitals’ Labor and Delivery Services

MedCity News

Addressing America’s maternal health crisis will be complicated and nuanced. Here are a few possible solutions. The post Rural America’s Maternity Crisis: How Locum Tenens Can Help Fill Gaps in Rural Hospitals’ Labor and Delivery Services appeared first on MedCity News.

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Conduit acquires three first-in-class assets from AstraZeneca 

Pharmaceutical Technology

Conduit plans to advance two assets, AZD1656 and AZD5658, into Phase II testing for autoimmune disorders.

105
105
article thumbnail

After a no in sickle cell, NICE OKs Casgevy for thalassaemia

pharmaphorum

NICE backs Vertex's gene-editing therapy Casgevy as a treatment for beta thalassaemia, a few months after turning it down for sickle cell disease

90
article thumbnail

Bavarian Nordic tops up US smallpox/mpox vaccine stockpile with $156.8m order

Pharmaceutical Technology

The contract will see bulk product for Jynneos replenished and additional services for dose storage.

96
article thumbnail

FDA Order on OTC Monograph Drugs Containing Acetaminophen Gets Renewed Comment Period

PharmaTech

The reopening of comments addresses the addition of a warning to consumers that acetaminophen may cause skin irritation characterized by reddening, blisters, and rashes.

FDA 69
article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

Looking Ahead to Medicare Reforms Coming in 2025

Pharmaceutical Commerce

Will the looming changes address the concerns of the patient assistance community?

article thumbnail

Market share shakeup: Big Pharma’s bestselling drugs drive industry shifts in 2024’s first half

PharmaVoice

The top drugs at each of the world’s most valuable pharma companies tell the story of just how much the industry has changed over the course of a few years.

article thumbnail

The 7 insights you need for a successful IP strategy

Clarivate

Data might be the most valuable commodity on earth. When analyzed correctly, it can help businesses understand patterns and trends, opportunities and risks, standards and benchmarks. However, like any commodity, raw data alone has its limitations. When it comes to intellectual property (IP), the true value emerges when data is enriched. Enriched data improves search efficiency, saves time by quickly identifying relevant documents, provides clear and standardized abstracts, offers comprehensive g

article thumbnail

Researchers develop ‘magnetic vine robots’ to transform cancer treatment

PharmaTimes

Lung cancer accounts for an estimated two million global diagnoses and 1.

94
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

CRISPR-based Casgevy is made accessible in England following NICE guidance

Pharmaceutical Technology

The gene editing therapy will now be accessible to NHS England patients with beta-thalassemia, potentially replacing lifelong transfusions.

article thumbnail

Personalised mRNA cancer therapy shown to boost immune response

European Pharmaceutical Review

An investigational, individualised neoantigen therapy, with personalised encoded mRNA, has demonstrated potential to enable patient’s immune system to target cells that cause cancer. Researchers from the related study highlighted that it has been challenging to develop engineering therapies that give the immune system enough training to identify a patient’s neoantigens.

article thumbnail

Roche licenses Sangamo’s technology for another shot at Alzheimer’s drugs

PharmaVoice

Through a new deal, Roche has exclusive rights to Sangamo molecules designed to repress the gene that makes “tau,” a protein many scientists view as a main driver of Alzheimer’s.

52
article thumbnail

LEO Pharma's Patient-Centric Approach

PharmExec

In this part of his Pharmaceutical Executive video interview, Brian Hillberdink, EVP, LEO Pharma and President of LEO Pharma's US affiliate, discusses how is LEO Pharma positioning itself to capitalize on the unmet needs, patient centric initiatives, and more.

Pharma 52
article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A